Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of R/R AML

Leukemia, Myeloid, Acute Clinical Trial

Official title:

A Multi-center, Prospective, Single-arm Study of Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of Refractory/Relapsed Acute Myelogenous Leukemia (R/R AML)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05305859
• Other study ID #: FXMH-AML-001
• Secondary ID: ChiCTR2200056657
• Status: Recruiting
• Phase: Phase 2
• Start date: April 1, 2022
• Est. completion date: January 31, 2026

Study information

• Verified date: December 2023
• Source: The First Affiliated Hospital of Xiamen University
• Contact: Bing Xu, M.D.
• Phone: +865922137255
• Email: xubingzhangjian[@]126.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety and efficacy of Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of relapsed and/or refractory AML

Description:

Patients with relapsed and/or refractory AML have inferior outcomes. The regimen of Venetoclax and Azacitidine has been widely used in the treatment of RR AML and has proved to achieve CR rate of 30% ~ 40%. However, the median duration of response (DOR) of this regimen is about one year. Chidamide is a histone deacetylase (HDAC) inhibitor and preclinical data showed adding low-dose Chidamide to venetoclax could significantly promoted apoptosis of leukemia cell lines. Meanwhile, the Venetoclax Combining Chidamide and Azacitidine (VCA) regimen was applied to 2 patients with refractory AML. This regimen was well tolerated and both patients achieved CR after one cycle. Thus, we register this clinical trial and evaluate the safety and efficacy of VCA regimen.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: January 31, 2026
• Est. primary completion date: January 31, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age =18
• Relapsed and refractory patients with acute myeloid leukemia via morphology and immunology
• ECOG:0-2
• Life expectancy = 3 months
• Adequate laboratory parameters during the screening period as evidenced by the

following:

1. Creatinine clearance=30 mL/min and serum Creatinine = 160µmol/L

2. ALT and AST = 3 × upper limit of normal (ULN)

3. Able to understand and sign an informed consent form (ICF).

Exclusion Criteria:

• Diagnosis of acute promyelocytic leukemia (APL)
• Central nervous system leukemia
• Uncontrolled or significant cardiovascular disease, including any of the following:

1. Bradycardia of less than 50 beats per minute, unless the subject has a pacemaker; Diagnosis of or suspicion of long QT syndrome (including family history of long QT syndrome);

2. Systolic blood pressure =180 mmHg or diastolic blood pressure =110 mmHg; History of clinically relevant ventricular arrhythmias (eg, ventricular tachycardia, ventricular fibrillation, or Torsade de Pointes);

3. History of second (Mobitz II) or third degree heart block (subjects with pacemakers are eligible if they have no history of fainting or clinically relevant arrhythmias while using the pacemaker);

4. History of uncontrolled angina pectoris or myocardial infarction within 6 months prior to Screening;

5. History of New York Heart Association Class 3 or 4 heart failure;

6. Complete left bundle branch block;

7. Known history of left ventricular ejection fraction (LVEF) =45% or less than the institutional lower limit of normal;

• Active acute or chronic systemic fungal, bacterial, or viral infection not well controlled by antifungal, antibacterial or antiviral therapy;
• Suffered from other non-myeloid malignancies within 2 years, except adequately treated non-melanoma skin cancer, curatively treated in-situ disease, or other solid tumors curatively treated with no evidence of disease
• Females who are pregnant or breastfeeding;
• Mental disorders that hinder research participation
• Previous solid organ transplantation (SCT treatment is allowed in advance, but if the patient has GVHD or is still receiving immunosuppression/GVHD treatment, it is not allowed)
• Any other situation where the investigator believes that the patient should not participate in this trial

Related Conditions & MeSH terms

• Leukemia
• Leukemia, Myeloid
• Leukemia, Myeloid, Acute
• Refractory Leukemia
• Relapsed Adult AML

Intervention

Drug:
• venetoclax combining chidamide and azacitidine (VCA)
information already included in arm/group descriptions

Locations

Country	Name	City	State
China	Bing Xu	Xiamen	Fujian

Sponsors (7)

Lead Sponsor	Collaborator
The First Affiliated Hospital of Xiamen University	Dongguan People's Hospital, Fujian Cancer Hospital, Fujian Provincial Hospital, Huizhou Municipal Central Hospital, Jieyang People's Hospital, Zhangzhou manicipal hospital of Fujian Province

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Complete remission (CR) rate	CR was <5% marrow blasts by morphology	2 months
Secondary	1 year leukemia free survival (LFS)	Leukemia-free survival (LFS) is defined as survival without evidence of relapse from treatment initiation	1 year from treatment initiation
Secondary	1year overall survival (OS)	Overall survival(OS)is defined as the time from treatment initiation to death from any cause.	1 year from treatment initiation
Secondary	Adverse events	Adverse event is defined as any untoward medical occurrence associated with treatment	2 months
Secondary	objective response rate (ORR)	ORR is defined as CR, CRi and PR. Partial remission (PR) is defined as a decrease of at least 50% in the percentage of blasts to 5 to 25% in the bone marrow aspirate and the normalization of blood counts.	2 months